{
    "clinical_study": {
        "@rank": "53500", 
        "arm_group": [
            {
                "arm_group_label": "Treatment period 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment period 2", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Treatment period 3", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to compare the efficacy of\n      repaglinide to glyburide and placebo on hepatic glucose metabolism in subjects with type 2\n      diabetes."
        }, 
        "brief_title": "Efficacy of Repaglinide in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes\n\n          -  HbA1c (glycosylated haemoglobin A1c) above 7 %\n\n          -  BMI (body mass index) below 32 kg/m^2\n\n          -  FBG (fasting blood glucose) after wash out period 130-220 mg/dl\n\n          -  Currently treated with diet or OHA (oral hypoglycaemic agent)\n\n        Exclusion Criteria:\n\n          -  Current systemic treatment with concomitant medication\n\n          -  Known or suspected history of drug or alcohol dependence\n\n          -  Any other significant concomitant disease such as cerebrovascular or symptomatic\n             peripheral vascular disease, malignant, disease or severe treated or untreated\n             hypertension\n\n          -  Hepatic disease\n\n          -  Cardiac problems\n\n          -  Active proliferative retinopathy\n\n          -  Known or suspected allergy to trial product or related products\n\n          -  Women in fertile age and women having the intention of becoming pregnant\n\n          -  Body Mass Index (BMI) above 32 kg/m^2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698931", 
            "org_study_id": "AGEE-1259"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment period 1", 
                    "Treatment period 2", 
                    "Treatment period 3"
                ], 
                "description": "1 mg before each main meal on three separate dosing visits separated by a wash-out period", 
                "intervention_name": "repaglinide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment period 1", 
                    "Treatment period 2", 
                    "Treatment period 3"
                ], 
                "description": "5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period", 
                "intervention_name": "glyburide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment period 1", 
                    "Treatment period 2", 
                    "Treatment period 3"
                ], 
                "description": "Before each main meal on three separate dosing visits separated by a wash-out period", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Repaglinide", 
                "Glyburide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 1, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Padova", 
                    "country": "Italy", 
                    "zip": "35137"
                }
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy of Repaglinide Compared to Glyburide and Placebo on Hepatic Glucose Metabolism in Type 2 Diabetic Subjects Treated With Diet or With Antidiabetic Oral Agents. A Randomized, Open, Cross-over Single-centre Placebo-controlled Trial", 
        "overall_official": {
            "affiliation": "Novo Nordisk Farmaceutici SpA", 
            "last_name": "Letizia Vitali", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Basal hepatic glucose production", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698931"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of hypoglycaemic episodes", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Change in body weight", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Number of adverse events", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}